TITLE

DRAGON GETS HUMAN G-CSF LICENSING RIGHTS EXCLUDING CHINA

PUB. DATE
June 2004
SOURCE
Worldwide Biotech;Jun2004, Vol. 16 Issue 6, p4
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on a license agreement between Dragon Pharmaceutical Inc. of Vancouver, British Columbia and Suzhou Zhongkai Bio-Pharmaceuticals Co. Limited to commercialize the Recombinant Human Granulocyte Colony Stimulating Factor (rhG-CSF) product worldwide excluding China. Remarks from Alexander Wick, president and CEO of Dragon Pharmaceuticals, regarding the exclusion of China in the agreement; Features of the rhG-CSF product; Information on the Suzhou Zhongkai Bio-Pharmaceuticals and Dragon Pharmaceutical.
ACCESSION #
13265030

 

Related Articles

  • U. of Akron research draws licensing deal. Robinson, Ruthann // Crain's Cleveland Business;5/13/2002, Vol. 23 Issue 19, p5 

    Reports the license agreement between CathNet-Science and the University of Akron Research Foundation for the nitric oxide-releasing compound. Biotechnology to help speed the healing process among heart patients; Terms of the agreement; Number of technology-transfer licensing agreement...

  • PSMA LICENSES ALPHAVAX ARV FOR PROSTATE CANCER VACCINE.  // Biotech Business;Oct2001, Vol. 14 Issue 10, p1 

    Reports the licensing agreement between PSMA Development Co. LLC, Cytogen Corp. and AlphaVax Human Vaccines Inc. for the creation of a prostate cancer vaccine using the AlphaVax Replicon Vector system.

  • A Pilot Survey on the Licensing of DNA Inventions. Henry, Michelle R.; Cho, Mildred K.; Weaver, Meredith A.; Merz, Jon F. // Journal of Law, Medicine & Ethics;Fall2003, Vol. 31 Issue 3, p442 

    Reports on the results of pilot survey on licensing of DNA interventions. Patenting strategies; Licensing practices; Difficult issues in licensing negotiations.

  • Value drivers in licensing deals. Arnold, Katie; Coia, Anthony; Saywell, Scott; Smith, Ty; Minick, Scott; Löffler, Alicia // Nature Biotechnology;Nov2002, Vol. 20 Issue 11, p1085 

    Determines the appropriate gauge on how the value of licensing deals in commercial biotechnology is identified, enhanced and captured. Three quantitative methods used to analyze biotechnology products; Value of product deals between biotechnology and pharmaceutical companies; Impact of the type...

  • Value creation and sharing among universities, biotechnology and pharma. Edwards, Mark G; Murray, Fiona; Yu, Robert // Nature Biotechnology;Jun2003, Vol. 21 Issue 6, p618 

    An analysis of deal structures in biotechnology from the past 25 years reveals that universities often neglect important economic aspects in their licensing agreements.

  • Gold in the ivory tower: equity rewards of outlicensing. Edwards, Mark; Murray, Fiona; Yu, Robert // Nature Biotechnology;May2006, Vol. 24 Issue 5, p509 

    The article focuses on issues and topics regarding university-biotech licensing agreements in the U.S. Over time, university-biotech licensing agreements have become more complex as biotech companies increasingly relied upon academic discoveries a the foundation of their technology value....

  • OTHER NEWS TO NOTE.  // BioWorld Today;6/7/2010, Vol. 21 Issue 108, p6 

    This section offers news briefs concerning the biotechnology industries, which include the licensing agreement between Ascalon International Inc. and CerRx Inc., the agreement between Emisphere Technologies Inc. and Novartis AG and preclinical data on the dual agonist of Toll-like Receptor 7...

  • OTHER NEWS TO NOTE.  // BioWorld Today;2/2/2010, Vol. 21 Issue 21, p3 

    This section offers news briefs on the biotechnology industry including an exclusive worldwide licensing deal signed by Abbott with Pierre Fabre SA, the execution of a license agreement by Achillion Pharmaceuticals Inc. for elvucitabine, and the research agreements signed by Asuragen Inc. with...

  • Extracting Maximum Value from Your Patent Portfolio. Kaufman, Craig R. // BioPharm International;May2003, Vol. 16 Issue 5, p24 

    Discusses the importance of market surveillance and an effective litigation or licensing strategy for effective use of a patent portfolio in the biopharmaceutical industry. Prelitigation techniques; Infringement detection; Imposition of notice requirement on patent owners.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics